Seattle Genetics gains on Phase II mCRC data from Cascadian candidate
Newly released data showed Seattle Genetics’ tucatinib met the primary endpoint in the Phase II MOUNTAINEER trial for metastatic colorectal cancer, marking the first sign of fruit from its $614 million acquisition of Cascadian Therapeutics last year.
Data released in an abstract ahead of a presentation at the European Society for Medical Oncology (ESMO) meeting in Barcelona showed that among 22 evaluable HER2-amplified metastatic CRC patients, HER2 inhibitor tucatinib plus Herceptin trastuzumab led to a 55% overall response rate (ORR), as well as median progression-free and overall survival of 6.2 and 17.3 months, respectively...
BCIQ Company Profiles
BCIQ Target Profiles
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)